Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyorin Pharmaceutical CoTSE:4569 -0.69%70 EV-to-EBIT is 23.05 as of Aug. 23, 2026, which is 73% above its 10-year median of 13.35. GuruFocus rates TSE:4569 with a GF Score™ of 70/100 and a GF Value™ of 円1,579.57 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 694 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks worse than 63.83% on this metric.
Kyorin Pharmaceutical Co (TSE:4569) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kyorin Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円103,203 Mil.
Kyorin Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,159 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co EV-to-EBIT Related Terms
Kyorin Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyorin Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kyorin Pharmaceutical Co's EV-to-EBIT falls into.
Kyorin Pharmaceutical Co's current Enterprise Value is 円72,811 Mil.
Kyorin Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,159 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyorin Pharmaceutical Co (TSE:4569) has a EV-to-EBIT of 23.05 as of Aug. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kyorin Pharmaceutical Co and its competitors. This is 73% above median its historical median of 13.35. Over the past decade, Kyorin Pharmaceutical Co's EV-to-EBIT has ranged from 5.04 to 23.05. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #443 out of 694 companies in the Drug Manufacturers industry, placing it in the top 63.8%.
Is Kyorin Pharmaceutical Co's EV-to-EBIT too high?
Kyorin Pharmaceutical Co's current EV-to-EBIT of 23.05 is 73% above median its 10-year median of 13.35. Over the past 10 years, this metric has ranged from a low of 5.04 to a high of 23.05. The Drug Manufacturers industry median EV-to-EBIT is 15.70. Kyorin Pharmaceutical Co's value of 23.05 is 46.9% above this industry median. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #443 out of 694 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #443 out of 694 companies for EV-to-EBIT. This places Kyorin Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.70. Kyorin Pharmaceutical Co's value of 23.05 is 46.9% above this benchmark. Historically, Kyorin Pharmaceutical Co's own EV-to-EBIT has ranged from 5.04 to 23.05 over the past decade. While the company's 10-year median is 13.35 vs. the industry median of 15.70, Kyorin Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.70, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyorin Pharmaceutical Co's current EV-to-EBIT of 23.05 is 46.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kyorin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyorin Pharmaceutical Co's current EV-to-EBIT is 23.05, which is 73% above median its own 10-year median of 13.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,579.57, compared to a current price of 円1,158.00 — trading 26.7% below its estimated fair value. The current EV-to-EBIT is 23.05, which is 73% above median its 10-year median of 13.35 and 46.9% above the Drug Manufacturers industry median of 15.70. Kyorin Pharmaceutical Co's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current EV-to-EBIT is 23.05 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円1,158.00 is trading 26.7% below its estimated GF Value™ of 円1,579.57.
GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4569:
EV-to-EBIT: 23.05 (73% above median its 10-year median of 13.35)
GF Value™: 円1,579.57 vs. price of 円1,158.00 (26.7% below fair value)
Industry Position: 46.9% above the Drug Manufacturers median (#443 of 694)
No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
70GF Score
Get the complete analysis for TSE:4569
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4569 has been successfully added to your 
